CURC is 1st clinic in USA to include a patient in treatment in RhoVac’s clinical phase IIb study

First patient in treatment in RhoVac’s clinical phase IIb study in the USA

Click here to read more.

Results from the phase III study of nadofaregene firadenovec: Safety and efficacy in patients with high-grade, BCG-unresponsive Non-Muscle Invasive Bladder Cancer

Speaker: N. Shore, Myrtle Beach (US)   Event: 35th Annual EAU Congress – Virtual (EAU20V)
 

Dr. Shore joins the Duke Global Health Institute Board of Advisors

Dr. Neal D. Shore has been invited to join the prestigious Duke Global Health Institute Board of Advisors

The inaugural board of advisors for Duke Global Health Institute, founded in 2009, was composed of 14 visionary members who embraced Duke’s vision to build a world-class program that would lead its peers in the charge to address global health disparities. The work of that group played a vital role in developing DGHI into the establishment it is today, with over 400 students and 100 faculty from 8 Duke schools, conducting research in over 40 countries.

The DGHI board of advisors is entering its own phase of growth, from 15 to 25 members over the next five years. DGHI values board service and seeks to: 1) cultivate members’ interest in global health by providing opportunities for learning, meaningful discourse and interaction with leaders in the field; 2) honor its members’ contribution of time and effort by enlisting guidance and expertise on matters for which they can be most impactful; 3) foster in its members a sense of inspiration and purpose by facilitating interaction with students, faculty and staff; and 4) create an experience that deepens members’ affinity and connection to Duke University.

In creating a positive and engaging board experience, DGHI aims to empower its advisory board members to serve in a variety of ways: as thought partners, champions, investors and ambassadors who facilitate relationships and opportunities that support its mission. The DGHI advisory board convenes twice annually, once in the spring and another in the fall. Spring meetings rotate between New York, NY and Washington, DC; and fall meetings meet in Durham, NC. Terms of service last three years, and are renewable once by mutual agreement.

Dr. Shore’s educational and professional background, philanthropic investments, and alumnus status made him a fortuitous addition.

Click here to read more about The Duke Global Health Institute.

Open Label Phase II Study of Enzalutamide With Concurrent Administration of Radium 223 Dichloride in Patients With Castration-Resistant Prostate Cancer

Presented by: Neal D. Shore, Paul F. Schellhammer, Ronald F. Tutrone, Neil F. Mariados, Stacey S. Harrelson

Click here to read more.

Olaparib for Metastatic Castration-Resistant Prostate Cancer- Published in The NEW ENGLAND JOURNAL of MEDICINE

Johann de Bono, M.B., Ch.B., Ph.D., Joaquin Mateo, M.D., Ph.D., Karim Fizazi, M.D., Ph.D., Fred Saad, M.D., Neal Shore, M.D., Shahneen Sandhu, M.D., Kim N. Chi, M.D., Oliver Sartor, M.D., Neeraj Agarwal, M.D., David Olmos, M.D., Ph.D., Antoine Thiery-Vuillemin, M.D., Ph.D., Przemyslaw Twardowski, M.D., et al.

Click here to read more.

Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer- Published in The NEW ENGLAND JOURNAL of MEDICINE

Neal D. Shore, M.D., Fred Saad, M.D., Michael S. Cookson, M.D., M.M.H.C., Daniel J. George, M.D., Daniel R. Saltzstein, M.D., Ronald Tutrone, M.D., Hideyuki Akaza, M.D., Alberto Bossi, M.D., David F. van Veenhuyzen, M.B., Ch.B., M.Pharm.Med., Bryan Selby, M.S., Xiaolin Fan, Ph.D., Vicky Kang, M.D., et al., for the HERO Study Investigators*

Click here to read more.

Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer- Published in The NEW ENGLAND JOURNAL of MEDICINE

Presented by: Cora N. Sternberg, M.D., Karim Fizazi, M.D., Ph.D., Fred Saad, M.D., Neal D. Shore, M.D., Ugo De Giorgi, M.D., Ph.D., David F. Penson, M.D., M.P.H., Ubirajara Ferreira, M.D., Ph.D., Eleni Efstathiou, M.D., Ph.D., Katarzyna Madziarska, M.D., Ph.D., Michael P. Kolinsky, M.D., Daniel I. G. Cubero, M.D., Ph.D., Bettina Noerby, M.D., et al., for the PROSPER Investigators*

Click here to read more.

Olaparib for Metastatic Castration-Resistant Prostate Cancer

Presented by: Johann de Bono, M.B., Ch.B., Ph.D., Joaquin Mateo, M.D., Ph.D., Karim Fizazi, M.D., Ph.D., Fred Saad, M.D., Neal Shore, M.D., Shahneen Sandhu, M.D., Kim N. Chi, M.D., Oliver Sartor, M.D., Neeraj Agarwal, M.D., David Olmos, M.D., Ph.D., Antoine Thiery-Vuillemin, M.D., Ph.D., Przemyslaw Twardowski, M.D., et al.

Click here to read more.

SUO 2019: Overview of Clinical Research Process and Clinical Trials Structure

Presented by: Neal Shore, MD, FACS, Medical Director of the Carolina Urologic Research Center, Atlantic Urology Clinics, Myrtle Beach, South Carolina

Click here to read more.

Results of a Real-world Study of Enzalutamide and Abiraterone Acetate With Prednisone Tolerability (REAAcT)

Neal D. Shore, Daniel Saltzstein, Paul Sieber, Bryan Mehlhaff, Lawrence Gervasi, Jennifer Phillips, Yu-Ning Wong, Huiling Pei, Tracy McGowan

Click here to read more.